Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PDSB | EFFECT | bearish | 6/10 | PDS Biotechnology Corp's $200M shelf registration (S-3) became effective on 2026-07-21, allowing the company to issue co | Jul 22, 2026 |
| LYEL | EFFECT | neutral | 4/10 | Lyell Immunopharma's S-3 shelf registration (File No. 333-297433) became effective on July 21, 2026. This allows selling | Jul 22, 2026 |
| OTLK | EFFECT | neutral | 5/10 | The SEC declared effective Outlook Therapeutics' S-3 shelf registration statement on July 21, 2026. This allows the comp | Jul 22, 2026 |
| ICLR | 6-K | neutral | 4/10 | ICON plc filed a 6-K on July 22, 2026, solely to announce the scheduling of its Q2 2026 earnings release for July 29, 20 | Jul 22, 2026 |
| RADX | 6-K | bullish | 7/10 | Radiopharm Theranostics announced positive clinical data from two programs: RAD204 Phase 1 achieved a confirmed partial | Jul 22, 2026 |
| TLSA | 6-K | neutral | 3/10 | Executive Chairman and Founder Gabriele Cerrone purchased 42,357 common shares at $0.99 per share, increasing his total | Jul 22, 2026 |
| NRXP | 8-K | bullish | 6/10 | NRX Pharmaceuticals' subsidiary NRX Defense Systems received a letter from DARPA indicating its SPARC-TMS clinical trial | Jul 22, 2026 |
| OKYO | 6-K | neutral | 3/10 | OKYO Pharma's Chief Medical Officer Flavio Mantelli purchased 20,000 ordinary shares on Nasdaq at $1.40 per share, a $28 | Jul 22, 2026 |
| SMMT | 8-K | bullish | 7/10 | Summit Therapeutics reported updated overall survival (OS) data from the Phase III HARMONi trial of ivonescimab plus che | Jul 22, 2026 |
| MNPR | 8-K | bullish | 6/10 | Monopar Therapeutics initiated the rolling submission of a New Drug Application (NDA) for ALXN1840 (tiomolibdate choline | Jul 22, 2026 |
| TRIB | 6-K | neutral | 3/10 | Trinity Biotech announced a mandatory ADS ratio change from 1 ADS representing 20 Class A ordinary shares to 1 ADS repre | Jul 22, 2026 |
| TRIB | 6-K | neutral | 4/10 | Trinity Biotech announced a strategic collaboration and planned equity investment in Latch Medical to combine its CGM+ w | Jul 22, 2026 |
| LBRX | 8-K | bullish | 6/10 | LB Pharmaceuticals announced accelerated timing for topline results from its pivotal Phase 3 NOVA-2 trial of LB-102 in s | Jul 22, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's Laboratories filed a routine 6-K on July 22, 2026, disclosing the grant of 15,933 stock options to an eligib | Jul 22, 2026 |
| BIAF | 8-K | neutral | 3/10 | bioAffinity Technologies announced a collaboration with Pictor, Inc. to develop and commercialize next-generation diagno | Jul 22, 2026 |
| RDY | 6-K | neutral | 2/10 | Two 6-K filings from Dr. Reddy's Laboratories filed on July 22, 2026, each contain exhibits (PDF, HTML, and graphics) wh | Jul 22, 2026 |
| KAPA | 8-K | neutral | 4/10 | Kairos Pharma entered into an Investigator Initiated Research (IIR) agreement with Bayer, under which Bayer will supply | Jul 22, 2026 |
| NRSN | 6-K | mixed | 5/10 | NeuroSense Therapeutics announced it will proceed with a New Drug Submission (NDS) to Health Canada for PrimeC in ALS, f | Jul 22, 2026 |
| OKYO | PRESS-RELEASE | bullish | 4/10 | OKYO Pharma Chairman Gabriele Cerrone, through Panetta Partners Ltd, purchased 22,500 ordinary shares at $1.45 per share | Jul 22, 2026 |
| OKYO | 6-K | neutral | 3/10 | OKYO Pharma Chairman Gabriele Cerrone purchased 22,500 ordinary shares at $1.45 per share, increasing his total holdings | Jul 22, 2026 |
| RGEN | 425, 8-K | bullish | 7/10 | Repligen announced a definitive agreement to acquire BioLife Solutions for approximately $1.5 billion in a cash-and-stoc | Jul 22, 2026 |
| LLY | PRESS-RELEASE | neutral | 1/10 | Eli Lilly and Company announced it will host a conference call on August 5, 2026 to discuss its Q2 2026 results. | Jul 22, 2026 |
| OKYO | 6-K | neutral | 3/10 | OKYO Pharma disclosed via 6-K that Chief Development Officer and Director Gary S. Jacob purchased 3,500 ordinary shares | Jul 22, 2026 |
| TOI | CLUSTER | neutral | 2/10 | A mixed insider cluster at Oncology Institute, Inc. (TOI) saw CMO Yale Podnos sell $116K in shares on July 14 while 10% | Jul 22, 2026 |
| PCRX | PRESS-RELEASE | neutral | 1/10 | Pacira BioSciences announced it will report its Q2 2026 results on August 4, 2026. | Jul 22, 2026 |
| MNPR | PRESS-RELEASE | bullish | 7/10 | Monopar Therapeutics initiated a rolling NDA submission to the FDA for ALXN1840 (tiomolibdate choline), a first-in-class | Jul 22, 2026 |
| LBRX | PRESS-RELEASE | bullish | 6/10 | LB Pharmaceuticals announced that its pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia is enrolling faster than e | Jul 22, 2026 |
| RGEN | PRESS-RELEASE | bullish | 7/10 | Repligen acquires BioLife Solutions for $1.5B (64% stock, 36% cash), paying $31.00/share, a 24% premium to the 90-day VW | Jul 22, 2026 |
| GNTA | PRESS-RELEASE | neutral | 4/10 | Genenta Science (GNTA) reported FY2025 results for its 19%-owned affiliate Sòphia HT, showing 29.3% sales growth to €7.1 | Jul 22, 2026 |
| ELVN | CLUSTER | neutral | 2/10 | Two C-suite insiders at Enliven Therapeutics (ELVN) sold a combined $127K in open-market transactions on July 17, 2026. | Jul 22, 2026 |